Human trials of British coronavirus vaccine to widen to 10000

Henrietta Strickland
May 23, 2020

The vaccine, previously known as ChAdOx1 nCoV-19 and now as AZD1222, was developed by the University of Oxford and licensed to AstraZeneca.

Sarah Gilbert, professor of vaccinology at the Jenner Institute, said: "We have had a lot of interest already from people over the age of 55 years who were not eligible to take part in the phase I study, and we will now be able to include older age groups to continue the vaccine assessment".

The phase one trial involves giving vaccines in development to a limited number of people to see if it's safe and effective enough to move to wider trials.

To assess whether the vaccine works, Oxford's statisticians will compare the number of infections in the control group to the number of infections in the vaccinated group. "We are very grateful to the huge support of the trial volunteers in helping test whether this new vaccine could protect humans against the pandemic coronavirus".

CanSino uses a weakened common cold virus called an adenovirus - and Friday's study showed people whose bodies recognized that cold virus didn't get as much of the presumed COVID-19 benefit.

He penned an op-ed in the Washington Post about Moderna's claims earlier this week that its vaccine has seen favorable results in its trial.

There are now no approved treatments or vaccines for Covid-19.

Phase one, which began in April, involved just over 1,000 adult volunteers aged 18-55, being inoculated, following promising results on six monkeys in the United States in late March.

But Pollard acknowledged there were still many challenges ahead, including how long it will take to prove the vaccine works - particularly since transmission has dropped significantly in Britain - and any potential manufacturing complications.

Now the most valuable company on Britain's blue-chip FTSE 100 Index, AstraZeneca has already agreed to deliver 100 million doses to people in Britain, with 30 million as soon as September.

With leaders across the world surveying some of the worst economic destruction since at least World War Two and the deaths of more than 327,000 people, many are scrambling for a vaccine.

Adding: "There is uncertainty about how many cases there will be in the next three months". Scientists at Israel's Tel Aviv University and biopharmaceutical company Neovii, for example, recently announced a project to develop a COVID-19 vaccine.

During an interview with NPR's "Morning Edition" Friday, Fauci acknowledged the data hasn't been peer reviewed.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER